Department of Chemistry
Dr. Imtiyaz Yousuf
|Qualification :||PhD MSc JRF (NET)|
|Designation :||Assistant Professor|
|Thrust Area :||Bioinorganic, Synthetic Inorganic Chemistry, Organometallic Chemistry|
|Email :||firstname.lastname@example.org, email@example.com|
|Download :||Click here to download study materials|
|Online :||Click here to View Video Lectures|
Dr. Imtiyaz Yousuf did his B.Sc. and M.Sc. in chemistry from University of Kashmir, J & K. He was awarded UGC-CSIR JRF (NET) fellowship in Dec. 2010. He joined the Department of Chemistry, AMU as Junior Research Fellow (JRF) for his Ph.D studies in Inorganic Chemistry and was subsequently upgraded to Senior Research Fellow (SRF) in 2013. In 2015, he was awarded PhD in Chemistry. Later, in 2015, he joined the Department Of Chemistry, A.M.U, Aligarh as Assistant Professor. His research interests include the design and synthesis of novel metal-based chemotherapeutic agents and their interaction studies with biological targets. His recent interests include design and syntheses of Targeted Ru(II)-arene anticancer Complexes with high antitumor efficacy and lower systemic toxicity.
Synthesis, structural investigations and DNA cleavage properties of a new water soluble Cu(II)–iminodiacetate complex
Inorg. Chem. Commun., 106, 2019, 48–53
Recent advances in metallodrug-like molecules targeting non-coding RNAs in cancer chemotherapy,
Coord. Chem. Rev., 2019, 387, 47–59. (IF= 13.47)
Design and synthesis of a DNA intercalative half-sandwich organoruthenium(II)–chromone complex: cytotoxicity evaluation and topoisomerase Iα inhibition assay
New J. Chem., 2019, 43, 5475-5487 (I. F. = 3.26)
Single X-ray crystal structure, DFT studies and topoisomerase I inhibition activity of a tailored ionic Ag(I) nalidixic acid–piperazinium drug entity specific for pancreatic cancer cells
New J. Chem., 2018, 42, 506-519. (I. F. = 3.26)
Mechanistic insights of a novel chromone–appended Cu(II) anticancer drug entity: In vitro binding profile with DNA/RNA substrates and cytotoxic activity against MCF–7 and HepG2 cancer cells.
Dalton Trans. 2015, 44, 10330. (I. F. = 4.17)
Crystal Structure determination, spectroscopic characterization and biological profile of tailored antitumor ionic drug entity, Sn(IV) iminodiacetic acid-piperazinediium conjugate: In vitro DNA and RNA binding studies, Topo I inhibition, cytotoxic activity and systemic toxicity studies.
RSC Adv. 2015, 5, 6250. (I. F. = 3.70)
Enantiomeric fluoro–substituted benzothiazole Schiff base–valine Cu(II)/Zn(II) complexes as chemotherapeutic agents: DNA binding profile, cleavage activity, MTT assay and cell imaging studies.
J. Photochem. Photobiol. B. 2015, 143, 61. (I. F. = 3.03)
Design and synthesis of new Zn(II) nalidixic acid-DACH based Topo−II inhibiting molecular entity: Chemotherapeutic potential validated by its in vitro binding profile, pBR322 cleavage activity and molecular docking studies with DNA and RNA molecular targets.
Inorg. Chem. Acta. 2014, 421, 26. (I. F. = 2.01)
Synthesis, crystal structure and antiproliferative activity of Cu(II) nalidixic acid-DACH conjugate: Comparative in vitro DNA/RNA binding profile, cleavage activity and molecular docking studies.
L. Eur. J. Med. Chem. 2014, 81, 76. (I. F.= 4.5)